IDEAYA Biosciences, Inc. (IDYA)

NASDAQ: IDYA · USD

$33.9

+0.43 (+1.3%)· Recorded snapshot

Market cap	3.3B
Revenue (ttm)	234.1M
Net income (ttm)	-175M
EPS (ttm)	-$1.96
Shares out	96.5M
Volume	808,246
Beta	-0.04

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 234.1M
Net income (ttm): -175M
EPS (ttm): -$1.96
Market cap: 3.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-16.2

P25 n/aP50 n/aP75 n/a

ROIC-12.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All IDYA indicators

Market & fundamental data

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001676725
Company name	IDEAYA Biosciences, Inc.
Country	United States
Country code	US
CUSIP number	45166A102
Earnings date	2026-11-10
Earnings time	bmo
Employees	145
Employees change	14
Employees growth	10.69%
Enterprise value	$2.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2019-05-23
Is primary listing	Yes
Is SPAC	No
ISIN number	US45166A1025
Last 10-K release date	2026-02-17
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.3B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$33.93
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	IDYA
U.S. state	California
Website	https://www.ideayabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-5.77%
EV/Sales	8.79x
FCF / EV yield	-5.53%
FCF yield	-3.48%
Forward EV/Sales	36.96x
Forward P/S	58.76x
P/B ratio	2.69x
P/S ratio	13.97x
Price / tangible book value	2.73x
Sector forward P/E	23.56x
Sector P/E	50.09x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-92.66%
EBITDA margin	-91.49%
Gross margin	-59.75%
Operating margin	-92.66%
Pretax margin	-74.75%
Profit margin	-74.75%
Profit per employee	$-1.2M
Revenue per employee	$1.6M
ROA	-11.54%
ROA (5Y)	-13.51%
ROCE	-17.68%
ROE	-16.22%
ROE (5Y)	-20.96%
ROIC	-12.25%
SBC / revenue	23.58%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth	3,244.67%
Revenue growth (QoQ)	35.02%
Revenue growth 3Y	73.09%
Revenue growth 5Y	45.8%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.2M
Depreciation and amortization	$2.8M
EBIT	$-217M
EBITDA	$-214.2M
EPS	$-1.96
FCF per share	$-1.18
Financing cash flow	$362.8M
Free cash flow	$-113.9M
Free cash flow minus SBC	$-169.1M
Gross profit	$-139.9M
Investing cash flow	$-92.7M
Net cash flow	$158.4M
Net income	$-175M
Operating cash flow minus SBC	$-166.9M
Operating income	$-217M
Revenue	$234.1M
Stock-based compensation	$55.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	13.67
Book value per share	$12.44
Debt / equity	0.02
Long-term assets	$445.7M
Long-term liabilities	$28.1M
Net cash (debt)	$1.2B
Net cash / market cap	37.1%
Net cash growth	25.72%
Net debt / equity	-1.01
Piotroski F-Score	3
Property, plant and equipment	$30.5M
Shareholders' equity	$1.2B
Tangible book value	$1.2B
Tangible book value per share	$12.44
Total assets	$1.3B
Total cash	$829M
Total debt	$29.3M
Total liabilities	$110.8M
WACC	4%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.2
Current assets	$864M
Current liabilities	$82.7M
Current ratio	10.45
Net working capital	$-46.4M
Quick ratio	10.21
Working capital	$781.3M
Working capital turnover	0.33

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.12%
Dividend yield	0%
Shareholder yield	-2.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$34.30
1D price change	1.28%
1M price change	-7.5%
1M total return	-7.5%
1W price change	-4.02%
1W total return	-4.02%
1Y price change	4.85%
1Y return CAGR	4.85%
1Y total return	4.85%
20-day SMA	$35.25
200-day SMA	$34.05
3M price change	-7.7%
3M total return	-7.7%
3Y price change	32.73%
3Y return CAGR	9.9%
3Y total return	32.73%
50-day SMA	$37.51
50-day SMA vs 200-day SMA	50over200
52-week high	$42.68
52-week high date	2026-08-25
52-week low	$26.81
52-week low date	2026-06-10
5Y price change	57.28%
5Y return CAGR	9.48%
5Y total return	57.28%
6M price change	15.13%
6M total return	15.13%
All-time high	$47.74
All-time high date	2024-02-15
All-time low	$2.95
All-time low date	2020-03-17
Average true range (ATR)	$1.48
Average volume	795.7K
Beta (1Y)	0.86
Beta (2Y)	1.3
Beta (5Y)	-0.04
Change from 52-week high	-20.5%
Change from 52-week low	26.56%
Change from all-time high	-28.9%
Change from all-time low	1,050.51%
Change from open	2.54%
Day's gap	-1.22%
Dollar volume	$27.4M
High price	$34.18
Low price	$33.05
Monthly RSI	53.5
Open price	$33.09
Position in 52-week range	77.88%
Premarket change	-0.3%
Premarket close	$33.50
Premarket price	$33.40
Premarket volume	2K
Previous close	$33.50
Price vs 150-day SMA	-1.05%
Price vs 20-day SMA	-3.71%
Price vs 200-day SMA	-0.33%
Price vs 50-day SMA	-9.51%
Relative volume	1.02
Return from IPO open	142.18%
Return from IPO price	239.05%
RSI	41.71
Sharpe ratio	0.24
Sharpe ratio (3Y)	0.32
Sharpe ratio (5Y)	0.36
Sortino ratio	0.49
Sortino ratio (3Y)	0.6
Sortino ratio (5Y)	0.64
Volume	808.2K
Weekly RSI	47.57
YTD price change	-1.82%
YTD total return	-1.82%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	90.6M
Float percentage	93.93%
Shares change (QoQ)	3.79%
Shares change (YoY)	2.12%
Shares held by insiders	0.88%
Shares held by institutions	102.51%
Shares outstanding	96.5M
Short % of float	10.13%
Short % of shares	9.52%
Short ratio	10.7 days

Deeper analysis on IDYA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IDYA report

Is a complete IDYA research report available?

No complete published report is available for IDEAYA Biosciences, Inc. (IDYA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

IDEAYA Biosciences, Inc. (IDYA)

Price

Financial snapshot

Fair-value bridge

Latest news · IDYA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IDYA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IDYA

Frequently asked questions